BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/19/2024 10:56:31 AM | Browse: 440 | Download: 1321
Publication Name World Journal of Psychiatry
Manuscript ID 90856
Country China
ISSN 2220-3206 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Clinical Neurology
Manuscript Type Case Control Study
Article Title Evaluating serum CXCL12, sCD22, Lp-PLA2 levels and ratios as biomarkers for diagnosis of Alzheimer's disease
Manuscript Source Unsolicited Manuscript
All Author List Zeng-Ling Liu, Fei-Fei Hua, Lei Qu, Na Yan and Hui-Fang Zhang
ORCID
Author(s) ORCID Number
Hui-Fang Zhang http://orcid.org/0009-0004-2759-5304
Funding Agency and Grant Number
Corresponding Author Hui-Fang Zhang, MMed, Staff Physician, Department of Neurology, Dongying People's Hospital, No. 317 Dongcheng South 1st Road, Dongying District, Dongying 257000, Shandong Province, China. huifangzhang2@163.com
Key Words Alzheimer's disease; Biomarkers; CXCL12; sCD22; Lp-PLA2
Core Tip This study uncovers the diagnostic potential of serum CXCL12, sCD22, Lp-PLA2 levels, and their ratios in Alzheimer's disease (AD). The research reveals distinct patterns in these biomarkers among AD patients, providing insight into their roles in neuroinflammation and immune regulation. The findings suggest these serum markers, especially when combined as ratios, could enhance AD diagnosis, offering a non-invasive approach to early detection and intervention.
Publish Date 2024-03-19 10:56
Citation Liu ZL, Hua FF, Qu L, Yan N, Zhang HF. Evaluating serum CXCL12, sCD22, Lp-PLA2 levels and ratios as biomarkers for diagnosis of Alzheimer's disease. World J Psychiatry 2024; 14(3): 380-387
URL https://www.wjgnet.com/2220-3206/full/v14/i3/380.htm
DOI https://dx.doi.org/10.5498/wjp.v14.i3.380
Full Article (PDF) WJP-14-380-with-cover.pdf